key: cord-0883179-ma27jdwa
authors: Ballas, Zuhair K.
title: 2021: The year in review
date: 2022-01-22
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2022.01.006
sha: 50762b995f2f225541a66f2a808cc8f9a07fceb3
doc_id: 883179
cord_uid: ma27jdwa

nan

Just a few weeks after the introduction of highly effective vaccines, the calendar year 2021 dawned with the promise of controlling the COVID-19 pandemic. As is often the case in medicine, diseases and patients do not always follow the script. The interaction of scientific advances, humanity, and a virus bent on survival led to another year well outside the norm. If there is a silver lining to this pandemic, it has been realized in the hitherto unprecedented speed that led to the development of vaccines, mAbs, and oral medications aimed at controlling the virus. Another silver lining lies in the opening of whole new fields of research in immunology in general and the interface of the immune system with viral infections in particular. Although the studies in the first year of COVID-19 focused on stratifying severity and identifying helpful therapeutics, the second year (from an immunologic point of view) saw more of a focus on cytokine storms, multiorgan dysfunction, the presence of autoantibodies in patients who were asymptomatic until infected, and the de novo development of autoantibodies, including anti-type 1 interferon (and one assumes other cytokines) autoantibodies.

Although the scientific and medical worlds were focused on the virus, the indolent chronic diseases and social disparities continued unabated and perhaps worsened. Our mission at the Journal of Allergy and Clinical Immunology is to give equitable weight to all of these issues. This is reflected in the choice of themes, as well as in the selection of articles. We believe that our readers will readily recognize that we have covered basic, translational, clinical, and social aspects of our specialty in addition to COVID-19. Our themes for this year were as follows: food allergy, newborn screening for severe combined immunodeficiency, the genetics of asthma, anaphylaxis, innate immunity, Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity inflammasomes, the exposome, aspirin-exacerbated respiratory diseases, the immunology of pregnancy, Janus kinase inhibitors, social disparities in allergy/immunology, and global issues in allergy/immunology. As is readily apparent from these themes, we have strived to cover most topics with immediate relevance to our readers and the members of the American Academy of Allergy, Asthma & Immunology. This is not an easy task given the breadth of our specialty. One metric that we have used in selecting themes and articles is the interest of our readers as reflected in the number of downloads for each article. Table I indicates the top 10 most downloaded articles in 2021.

Another metric to measure our impact is the number of citations received by each article, which indicates the interest of the scientific community at large. The top 10 most cited articles are listed in Table II .

It is interesting to note that 5 of the top 10 downloaded articles are articles devoted to COVID-19. On the other hand, 9 of the top 10 cited articles are articles about COVID. Three of the articles appear in both lists. [1] [2] [3] The editors believe that sometimes highly impactful articles may be overlooked or their potential impact may not be immediately apparent. Hence, we have the Editors' Choice in each monthly issue. The editors reviewed the articles that were selected for Editors' Choice in 2021 and selected the 10 articles that they thought have or will have significant impact on our understanding of mechanisms or on our daily practice. These are shown in Table III .

The editors would like to extend heartfelt thanks and gratitude to our reviewers, who once again went above and beyond the call of duty to ensure fair and rapid reviews.

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

UK PIN COVID-19 Consortium. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19